Molecular subtyping drives confident treatment decisions for breast cancer
Human Breast Cancer Molecular Subtyping Quantitative Detection Kit(PCR-Fluorophore-labeling Probes)
China NMPA certified | CE Certified
Non-invasive, Instant, Home-based and Self-testing
Prediction and Screening of Pre-eclampsia in the 2nd and 3rd Trimester of Prenancy.
China NMPA certified | CE Certified
Latest News
Low Risk Patients Identified by MammaTyper® LRP Had Significantly Better DDFS and Did Not Benefit from Adjuvant Chemotherapy BERLIN, GERMANY, December 15, 2025 | Cerca Biotech., a Germany-based diagnostics company, announces the poster presentation at San Antonio Breast Cancer Symposium 2025 of a study highlighting the […]
The results from a prospective clinical study on CercaTest RED™ was presented in the Asia Pacific Congress in Maternal Fetal Medicine 2025 (APCMFM) held from November 1 to 3 in Osaka, Japan. The Asia-Pacific Congress of Maternal-Fetal Medicine (APCMFM) is one of the most influential academic […]
BERLIN, GERMANY, October 27, 2025 — Cerca Biotech., a German-based diagnostics company, announces the publication of a white paper highlighting the importance of molecular diagnostics in HER2-low breast cancer cases as a potential to improve the diagnostic complexity. MammaTyper® is a molecular diagnostic test from Cerca Biotech, a reverse transcription, […]
Screening, diagnosis & precision medicine for women’s health.
We are committed to becoming a global leader in innovative diagnosis and precision medicine focused on women’s health.
Precision Medicine for Breast Cancer
Precision Medicine for Oncology
Maternal Fetal Diagnostics & Health
Reproductive Tract Infection & Health